Zhejie Liu
Second Affiliated Hospital, Zhejiang University, School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Zhejie Liu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:40 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04067505 · Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS StudySecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · May-Thurner Syndrome · principal investigator
- Ph3NCT04066764 · Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava FiltersSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Venous Thromboembolism · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:40 UTC. The ranking covers the 200 most relevant of 2004 PubMed records, and a shared surname and initials can bring in a namesake. All 2004 on PubMed
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.N Engl J Med · 2023287 citationsRCR 36.7
- 265 citationsRCR 35.1
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol · 2023155 citationsRCR 13.3
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Br J Dermatol · 2023141 citationsRCR 19.2
- 139 citationsRCR 15.2
- Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.Nat Med · 2025139 citationsRCR 29.7
- Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.Nat Med · 2024130 citationsRCR 16.1
- 119 citationsRCR 11.8
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.Nat Med · 2024116 citationsRCR 17.4
- 112 citationsRCR 7.5